129 N. Hill, Suite 103
About Terray Therapeutics
Chemistry is the key to drug discovery, but chemical data is stuck in the twentieth century. We’re generating precise chemical datasets purpose-built to propel drug discovery into the information age — and we’re doing it on a larger scale and faster than has ever before been possible. Terray Therapeutics is a biotechnology company led by pioneers and long-time leaders in artificial intelligence, synthetic (medicinal) chemistry, biology and preclinical development, automation, and nanotechnology. Chemical datasets generated using our novel ultra-dense microarray technology work seamlessly with our integrated machine learning and computational platform to systematically map biochemical interactions between small molecules and causes of disease. Iterative cycles of virtual molecular design and experimentation power AI and machine learning models, which in turn guide the next cycle of design. With a chemistry engine that measures billions of interactions daily and becomes increasingly precise with every cycle, we can answer an unprecedented array of questions — deriving insights that enable us to predictably create drugs for patients in need.
11 articles about Terray Therapeutics
Terray Therapeutics today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as Strategic Advisor to the Board of Directors and Leadership Team.
Terray Therapeutics Strengthens Leadership with Appointment of Bassil Dahiyat, Ph.D., as Board Independent Director
Terray Therapeutics today announced the appointment of Bassil Dahiyat, Ph.D., as an Independent Director.
BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
Terray Therapeutics and Calico Life Sciences struck a research and development collaboration focused on the development of small-molecule therapeutics for age-related diseases.
Terray Therapeutics Expands Scientific Advisory Board to Advance AI-Driven Small Molecule Drug Discovery
Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointment of Fiona Black, PhD to its Scientific Advisory Board, adding valuable expertise in interdisciplinary technology development of both market-leading, end-to-end product solutions and operationally efficient and scalable manufacturing processes.
Kurma Partners earned €160 million in the first closing of its Growth Opportunities fund, and Atlas Venture raked in its largest round of funding yet to invest in new biotech firms.
Atlas Venture raised $450 million at the close of its thirteenth fundraising activity to support efforts to create and invest in new biotech firms that address many unmet patient needs.
3/4/2022Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Terray Therapeutics Expands Leadership Team with Fez Ujjainwalla, PhD as Head of Business and Adam D. Hughes, PhD as Head of Chemistry
Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, announced the appointments of Feroze Ujjainwalla, PhD, as Head of Business, and Adam D. Hughes, PhD, as Head of Chemistry.
Terray Therapeutics Launches with $60M to Deliver Premium Chemical Data at Unrivaled Scale, Unlocking the Potential of AI-Driven Small Molecule Drug Discovery
Terray Therapeutics today announced the closing of a $60 million Series A financing to advance its novel tNova platform and deliver therapies to patients faster than ever before.
Terray Therapeutics has generated $60 million from a Series A financing round just shortly after getting $20 million in seed funding for the AI drug discovery.